Lenalidomid Glenmark

Lenalidomide, the active ingredient in Lenalidomid Glenmark, is an immunomodulatory drug presented as a tablet for oral use. It is used in the treatment of certain blood cancers, primarily multiple myeloma and myelodysplastic syndromes, in adult patients. GNH USA supplies Lenalidomid Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomid Glenmark is an immunomodulatory agent indicated for specific hematologic malignancies. - Multiple Myeloma: improves progression‑free survival and overall response in patients with relapsed or refractory disease. - Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and corrects cytopenias. - Maintenance Therapy after Autologous Stem Cell Transplant in Multiple Myeloma: prolongs remission duration.

Lenalidomid Glenmark may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: lowered platelet levels leading to easy bruising. - Anemia: decreased red blood cells causing weakness. - Diarrhea: loose stools that may affect hydration. - Rash: mild skin irritation or erythema.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: profound immune suppression requiring medical intervention. - Severe thrombocytopenia: significant bleeding risk. - Secondary primary malignancies: emergence of new cancers. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: elevated liver enzymes or liver injury.

Before initiating therapy, clinicians should assess patient risk factors and monitor laboratory parameters regularly. - Pregnancy contraindication: teratogenic; ensure effective contraception for women of childbearing potential. - Thromboembolic risk: consider prophylactic anticoagulation in high‑risk patients. - Hematologic monitoring: perform complete blood counts weekly during the first two cycles. - Renal impairment: adjust dose or avoid use in severe renal dysfunction. - Drug interactions: review concomitant medications for CYP3A4 modulators. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lenalidomid Glenmark can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Thalidomide: additive teratogenic and neurotoxic effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase lenalidomide exposure. - Anticoagulants (e.g., warfarin, DOACs): heightened risk of thromboembolic events. - Live vaccines: reduced efficacy and potential infection risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower drug levels. - NSAIDs: increased bleeding tendency when thrombocytopenia is present. - Antihypertensives: possible additive hypotensive effect. - Digoxin: monitor serum levels due to potential pharmacodynamic changes.